Carregant...
Improved coagulation and hemostasis in hemophilia with inhibitors by combinations of (super)Factor Va and Factor VIIa
Bypassing inhibitors in hemophilia patients is limited to activated (a) Factor(F)VII products. We introduced “FVa activity augmentation” as another bypassing strategy and studied effects of an engineered FVa variant designated (super)FVa. Procoagulant and clot stabilizing properties of (super)FVa an...
Guardat en:
| Publicat a: | Thromb Haemost |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4775351/ https://ncbi.nlm.nih.gov/pubmed/26466980 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1160/TH15-07-0525 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|